Journal Article Summary
The article examines the role of real-world evidence (RWE) in the economic assessments of pharmaceuticals in the United States, particularly focusing on how this type of evidence is utilized by the Institute for Clinical and Economic Review (ICER). Understanding the use of RWE is important because it can provide insights into the effectiveness and value of medications based on actual patient experiences, rather than just clinical trial data. This is increasingly relevant as healthcare decision-makers seek to make informed choices about drug pricing and reimbursement.
The researchers analyzed 33 final evidence reports published by ICER, all of which incorporated RWE. They found that, on average, RWE informed about 32.7% of the model inputs in these reports, with a range from 4.1% to 76.9%. The most common applications of RWE were related to disease progression and healthcare resource utilization, while it was less frequently used for specific drug effectiveness outcomes. The study primarily relied on retrospective cohort designs and registry data, with a notable portion of the RWE being sponsored by the pharmaceutical industry.
Despite the findings, the study has limitations, including the potential bias from industry sponsorship and the limited use of RWE for drug-specific effectiveness outcomes. This raises questions about the reliability of RWE in fully capturing the real-world effectiveness of medications. Patients and caregivers should discuss these findings with healthcare professionals to better understand how RWE may impact treatment decisions and the overall value of medications they may be considering.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Lee Woojung, Dayer Victoria, Jiao Boshen, Carlson Josh J, Devine Beth, Veenstra David L. Use of real-world evidence in economic assessments of pharmaceuticals in the United States. Journal of Managed Care & Specialty Pharmacy 2021. DOI: 10.18553/jmcp.2021.27.1.005. PMID: 33377439. PMCID: PMC10390921.
Featured Pill Pals Product
Acetaminophen 500 MG Caplets ---1,000 Count --- Generic For Tylenol --- Major / Rugby --- Over The Counter
Acetaminophen 500 MG Caplets —1,000 Count — Generic For Tylenol — Major / Rugby — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
